Mark James Daniel - Oct 14, 2025 Form 4 Insider Report for ATOSSA THERAPEUTICS, INC. (ATOS)

Role
Chief Financial Officer
Signature
/s/ Mark James Daniel
Stock symbol
ATOS
Transactions as of
Oct 14, 2025
Transactions value $
$0
Form type
4
Date filed
10/21/2025, 04:10 PM
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Daniel Mark James Chief Financial Officer C/O ATOSSA THERAPEUTICS, INC., 10202 5TH AVENUE NE SUITE 200, SEATTLE /s/ Mark James Daniel 2025-10-21 0002092593

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATOS Stock Option (right to buy) Award $0 +578K $0.00 578K Oct 14, 2025 Common Stock 578K $1.03 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options shall vest with respect to 25% on October 14, 2026, with the remaining 75% to vest in equal quarterly installments over the follwing three years, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.